{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-034442","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.642069+00:00","generated_at":"2026-05-16T22:08:07.392705+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioCardia reports Q3 2025 results, $6M financing, and regulatory milestones for cell therapies","bullets":["Closed $6.0 million financing with net proceeds of $5.2 million in September 2025.","Net loss decreased to $1.5 million for Q3 2025 from $1.7 million in Q3 2024.","Positive preliminary clinical consultation with Japan’s PMDA for CardiAMP heart failure trial.","Plans to submit Helix transendocardial delivery catheter for FDA DeNovo 510(k) in Q4 2025.","Cash balance of $5.3 million on Sept 30, 2025, providing runway into Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-034442","json":"https://secwatch.observer/filing/0001437749-25-034442.json","markdown":"https://secwatch.observer/filing/0001437749-25-034442.md","text":"https://secwatch.observer/filing/0001437749-25-034442.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774925034442/0001437749-25-034442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774925034442/bcda20251112_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T22:08:07.392705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}